JQ1, a small molecule inhibitor of BRD4, suppresses cell growth and invasion in oral squamous cell carcinoma

Wang,Limei; Wu,Xiuyin; Huang,Ping; Lv,Zhijun; Qi,Yuping; Wei,Xiujuan; Yang,Pishan; Zhang,Fenghe

doi:10.3892/or.2016.5037

JQ1, a small molecule inhibitor of BRD4, suppresses cell growth and invasion in oral squamous cell carcinoma

Authors:
- Limei Wang
- Xiuyin Wu
- Ping Huang
- Zhijun Lv
- Yuping Qi
- Xiujuan Wei
- Pishan Yang
- Fenghe Zhang
View Affiliations

Affiliations: Department of Periodontology, School of Stomatology, Shandong University, Jinan, Shandong 250012, P.R. China, Shandong Provincial Key Laboratory of Oral Tissue Regeneration, Jinan, Shandong 250012, P.R. China, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Department of Stomatology, Laiwu City People's Hospital, Laiwu, Shandong 271100, P.R. China, Department of Stomatology, Qilu Hospital, and Institute of Stomatology, Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: August 24, 2016 https://doi.org/10.3892/or.2016.5037
Pages: 1989-1996

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to evaluate whether bromodomain 4 (BRD4) is expressed in Cal27 cells and to assess the effect of JQ1 on cell proliferation, apoptosis, invasion and BRD4, C-Myc and Twist expression in Cal27 cells. Immunofluorescence staining was used to determine whether BRD4 was expressed in Cal27 cells. Cell viability and proliferation were evaluated using CCK-8 assay. Flow cytometry was used to determine the apoptosis and cell cycle distribution. The cell invasion was evaluated using Transwell plate. The expression levels of BRD4, C-Myc and Twist were determined by quantitative RT-PCR (qRT-PCR) and western blotting. BRD4 was highly expressed in Cal27 cells. JQ1 inhibited cell proliferation, induced cell apoptosis, induced cell cycle arrest, and inhibited cell invasion. Gene and protein expression levels of BRD4, C-Myc and Twist were downregulated in cells treated with JQ1. JQ1 inhibited Cal27 cell growth and invasion, and downregulated expression of several oncogenes. JQ1 may be a new drug for oral squamous cell carcinoma treatment.

View Figures

View References

1	Omar E: Current concepts and future of noninvasive procedures for diagnosing oral squamous cell carcinoma - a systematic review. Head Face Med. 11:62015. View Article : Google Scholar :
2	Chiang CM: Brd4 engagement from chromatin targeting to transcriptional regulation: Selective contact with acetylated histone H3 and H4.F1000. Biol Rep. 1:982009.
3	Wu X, Liu D, Tao D, Xiang W, Xiao X, Wang M, Wang L, Luo G, Li Y, Zeng F, et al: BRD4 regulates EZH2 transcription through up-regulation of C-MYC and represents a novel therapeutic target in bladder cancer. Mol Cancer Ther. 15:1029–1042. 2016. View Article : Google Scholar : PubMed/NCBI
4	Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et al: BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 146:904–917. 2011. View Article : Google Scholar : PubMed/NCBI
5	Liao YF, Wu YB, Long X, Zhu SQ, Jin C, Xu JJ and Ding JY: High level of BRD4 promotes non-small cell lung cancer progression. Oncotarget. 7:9491–9500. 2016.PubMed/NCBI
6	Wedeh G, Cerny-Reiterer S, Eisenwort G, Herrmann H, Blatt K, Hadzijusufovic E, Sadovnik I, Müllauer L, Schwaab J, Hoffmann T, et al: Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia. Leukemia. 29:2230–2237. 2015. View Article : Google Scholar : PubMed/NCBI
7	Li GQ, Guo WZ, Zhang Y, Seng JJ, Zhang HP, Ma XX, Zhang G, Li J, Yan B, Tang HW, et al: Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression. Oncotarget. 7:2462–2474. 2016.
8	Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, et al: RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 478:524–528. 2011. View Article : Google Scholar : PubMed/NCBI
9	Shi J, Cao J and Zhou BP: Twist-BRD4 complex: Potential drug target for basal-like breast cancer. Curr Pharm Des. 21:1256–1261. 2015. View Article : Google Scholar
10	Wu T and Donohoe ME: The converging roles of BRD4 and gene transcription in pluripotency and oncogenesis. RNA Dis. 2:pii: e894. 2015.PubMed/NCBI
11	Leptin M: twist and snail as positive and negative regulators during Drosophila mesoderm development. Genes Dev. 5:1568–1576. 1991. View Article : Google Scholar : PubMed/NCBI
12	Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, Doglioni C, Beach DH and Hannon GJ: twist is a potential oncogene that inhibits apoptosis. Genes Dev. 13:2207–2217. 1999. View Article : Google Scholar : PubMed/NCBI
13	Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, Tang F, Chen ZQ, Liu XP and Xu ZD: Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res. 15:2657–2665. 2009. View Article : Google Scholar : PubMed/NCBI
14	Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD and Wang LH: Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res. 67:1979–1987. 2007. View Article : Google Scholar : PubMed/NCBI
15	Shi J, Wang Y, Zeng L, Wu Y, Deng J, Zhang Q, Lin Y, Li J, Kang T, Tao M, et al: Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. Cancer Cell. 25:210–225. 2014. View Article : Google Scholar : PubMed/NCBI
16	Wahlström T and Arsenian Henriksson M: Impact of MYC in regulation of tumor cell metabolism. Biochim Biophys Acta. 1849:563–569. 2015. View Article : Google Scholar
17	Dang CV: MYC on the path to cancer. Cell. 149:22–35. 2012. View Article : Google Scholar : PubMed/NCBI
18	Vita M and Henriksson M: The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol. 16:318–330. 2006. View Article : Google Scholar : PubMed/NCBI
19	Nesbit CE, Tersak JM and Prochownik EV: MYC oncogenes and human neoplastic disease. Oncogene. 18:3004–3016. 1999. View Article : Google Scholar : PubMed/NCBI
20	Lüscher B and Vervoorts J: Regulation of gene transcription by the oncoprotein MYC. Gene. 494:145–160. 2012. View Article : Google Scholar : PubMed/NCBI
21	Delgado MD and León J: Myc roles in hematopoiesis and leukemia. Genes Cancer. 1:605–616. 2010. View Article : Google Scholar
22	Rahl PB, Lin CY, Seila AC, Flynn RA, McCuine S, Burge CB, Sharp PA and Young RA: c-Myc regulates transcriptional pause release. Cell. 141:432–445. 2010. View Article : Google Scholar : PubMed/NCBI
23	Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al: Selective inhibition of BET bromodomains. Nature. 468:1067–1073. 2010. View Article : Google Scholar : PubMed/NCBI
24	Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, Gao Y, Cheng KA, Cohoon TJ, Qi J, et al: Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin Cancer Res. 19:6183–6192. 2013. View Article : Google Scholar : PubMed/NCBI
25	Lenhart R, Kirov S, Desilva H, Cao J, Lei M, Johnston K, Peterson R, Schweizer L, Purandare A, Ross-Macdonald P, et al: Sensitivity of small cell lung cancer to BET inhibition is mediated by regulation of ASCL1 gene expression. Mol Cancer Ther. 14:2167–2174. 2015. View Article : Google Scholar : PubMed/NCBI
26	Zhang L, Tong Y, Zhang X, Pan M and Chen S: Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth. Drug Des Devel Ther. 9:5851–5862. 2015.PubMed/NCBI
27	Henssen A, Thor T, Odersky A, Heukamp L, El-Hindy N, Beckers A, Speleman F, Althoff K, Schäfers S, Schramm A, et al: BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget. 4:2080–2095. 2013. View Article : Google Scholar : PubMed/NCBI
28	Loosveld M, Castellano R, Gon S, Goubard A, Crouzet T, Pouyet L, Prebet T, Vey N, Nadel B, Collette Y, et al: Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALL. Oncotarget. 5:3168–3172. 2014. View Article : Google Scholar : PubMed/NCBI
29	Georgy SR, Cangkrama M, Srivastava S, Partridge D, Auden A, Dworkin S, McLean CA, Jane SM and Darido C: Identification of a novel proto-oncogenic network in head and neck squamous cell carcinoma. J Natl Cancer Inst. 107:pii: djv152. 2015. View Article : Google Scholar : PubMed/NCBI
30	Yu J, Xie F, Bao X, Chen W and Xu Q: miR-300 inhibits epithelial to mesenchymal transition and metastasis by targeting Twist in human epithelial cancer. Mol Cancer. 13:1212014. View Article : Google Scholar : PubMed/NCBI
31	Wang YH, Sui XM, Sui YN, Zhu QW, Yan K, Wang LS, Wang F and Zhou JH: BRD4 induces cell migration and invasion in HCC cells through MMP-2 and MMP-9 activation mediated by the Sonic hedgehog signaling pathway. Oncol Lett. 10:2227–2232. 2015.PubMed/NCBI
32	Ambrosini G, Sawle AD, Musi E and Schwartz GK: BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells. Oncotarget. 6:33397–33409. 2015.PubMed/NCBI
33	Wang YH, Sui YN, Yan K, Wang LS, Wang F and Zhou JH: BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance. Oncol Rep. 33:1699–1706. 2015.PubMed/NCBI
34	Zhang Z, Ma P, Jing Y, Yan Y, Cai MC, Zhang M, Zhang S, Peng H, Ji ZL, Di W, et al: BET bromodomain inhibition as a therapeutic strategy in ovarian cancer by downregulating FoxM1. Theranostics. 6:219–230. 2016. View Article : Google Scholar : PubMed/NCBI
35	Gao X, Wu X, Zhang X, Hua W and Zhang Y, Maimaiti Y, Gao Z and Zhang Y: Inhibition of BRD4 suppresses tumor growth and enhances iodine uptake in thyroid cancer. Biochem Biophys Res Commun. 469:679–685. 2016. View Article : Google Scholar
36	Lochrin SE, Price DK and Figg WD: BET bromodomain inhibitors - a novel epigenetic approach in castration-resistant prostate cancer. Cancer Biol Ther. 15:1583–1585. 2014. View Article : Google Scholar
37	Baker EK, Taylor S, Gupte A, Sharp PP, Walia M, Walsh NC, Zannettino AC, Chalk AM, Burns CJ and Walkley CR: BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells. Sci Rep. 5:101202015. View Article : Google Scholar : PubMed/NCBI
38	McKeown MR and Bradner JE: Therapeutic strategies to inhibit MYC. Cold Spring Harb Perspect Med. 4:42014. View Article : Google Scholar
39	Kandela I, Jin HY and Owen K: Reproducibility Project: Cancer Biology: Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Elife. 4:e070722015. View Article : Google Scholar
40	Conacci-Sorrell M, McFerrin L and Eisenman RN: An overview of MYC and its interactome. Cold Spring Harb Perspect Med. 4:a0143572014. View Article : Google Scholar : PubMed/NCBI
41	Meyer N and Penn LZ: Reflecting on 25 years with MYC. Nat Rev Cancer. 8:976–990. 2008. View Article : Google Scholar : PubMed/NCBI
42	Entz-Werlé N, Stoetzel C, Berard-Marec P, Kalifa C, Brugiere L, Pacquement H, Schmitt C, Tabone MD, Gentet JC, Quillet R, et al: Frequent genomic abnormalities at TWIST in human pediatric osteosarcomas. Int J Cancer. 117:349–355. 2005. View Article : Google Scholar : PubMed/NCBI
43	da Silva SD, Alaoui-Jamali MA, Soares FA, Carraro DM, Brentani HP, Hier M, Rogatto SR and Kowalski LP: TWIST1 is a molecular marker for a poor prognosis in oral cancer and represents a potential therapeutic target. Cancer. 120:352–362. 2014. View Article : Google Scholar
44	Zheng L, Li N, Guo F, Jian XC, Jiang CH, Yin P, Min AJ and Huang L: Twist-related protein 1 enhances oral tongue squamous cell carcinoma cell invasion through β-catenin signaling. Mol Med Rep. 11:2255–2261. 2015.